A recent clinical trial demonstrated that 50% of patients with active early rheumatoid arthritis achieved clinical remission after one year of treatment with ENBREL plus methotrexate. The study also showed significant improvements in symptoms and joint damage, setting a new standard for earlier treatment of RA.
A study of psychiatrists and parents found significant differences in perceptions of pediatric ADHD and psychiatric comorbidities. The researchers suggest that improving communication between psychiatrists, parents, and patients can lead to better treatment outcomes for children with complicated ADHD.
A single dose of tolvaptan significantly increased urine volume and reduced pulmonary artery pressure, with more pronounced effects at higher doses. The study found no significant differences in cardiac output or other secondary outcomes.
Long-term treatment with VYVANSE shows significant efficacy in ADHD, with 95% of children experiencing overall improvement after 12 months. The study also found consistent time to maximum concentration of d-amphetamine from patient to patient.
A recent study found that guanfacine extended release significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years. The investigational nonstimulant medication demonstrated clinically meaningful efficacy for up to 24 months of treatment.
A double-blind study found DAYTRANA significantly reduced ADHD symptoms in boys and girls aged 6-12 by 56.5% and 57.4%, respectively. The patch offers a favorable safety profile and provides a platform to discuss gender differences in ADHD treatment.
Daytrana demonstrated significant improvements in symptom control, tolerability, and safety in children with ADHD over a 12-month period. The study showed effective treatment of ADHD symptoms, with 83% and 78% of parents reporting 'very much improved' or 'much improved' outcomes.
Researchers discovered a molecular mechanism that strengthens brain networks by closing ion channels, which may improve working memory and reduce distractibility in conditions like ADHD. This discovery has implications for developing drug therapies for normal aging and treating cognitive changes in schizophrenia and bipolar disorder.
The EVEREST trial showed that tolvaptan improved signs and symptoms of acutely decompensated heart failure, with significant reductions in body weight and improvements in dyspnea. Long-term use did not differ from placebo on survival endpoints, but tolvaptan may be a potential therapy for patients with heart failure.
Long-term Fosrenol treatment improves bone formation and reduces phosphorus levels in CKD stage 5 patients, according to a two-year study. The reformulated tablets also demonstrate efficacy as monotherapy for controlling serum phosphorus levels.
New data shows significant improvement in core symptoms of ADHD with guanfacine extended release, including hyperactivity, impulsivity, and inattention. The medication was well-tolerated with mild or moderate side effects.
A phase I clinical trial found that Shire's investigational drug SPD465 was bioequivalent to a combination of ADDERALL XR and mixed amphetamine salts immediate release. This suggests that SPD465 could offer full-day symptom control for adults with ADHD, potentially eliminating the need for augmenting long-acting stimulant medications.
A 25-year meta-analysis of 29 double-blind studies involving nearly 4,500 children with ADHD found that stimulant medications produced larger effect sizes than non-stimulants. The study suggests that amphetamine- and methylphenidate-based stimulants are more effective treatments for ADHD symptoms.
Patients with ankylosing spondylitis who received Enbrel treatment experienced sustained improvements in signs and symptoms, spinal mobility, and physical function over 148-160 weeks. A total of 78% of patients achieved a 20% improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS) after 160 weeks.
Enbrel, a biologic treatment, demonstrates sustained improvements in rheumatoid arthritis symptoms over up to nine years. Patients showed significant reductions in joint pain, stiffness, and disability.
The investigational amphetamine compound SPD465 demonstrated improved Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in adults for up to 16 hours post-dose. The study results showed that SPD465 provided significant improvement in ADHD symptom control based on PERMP and ADHD-RS scores.
A study found that adults with depressive disorder, Bipolar Disorder, or anxiety disorder are at risk of having undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), with 32.0% comorbid in those with depression and 21.2% in those with bipolar disorder. Researchers analyzed medical claims data to identify this comorbidity.
The DAYTRANA patch offers flexible wear times, allowing physicians to manage ADHD symptoms and minimize late-day side effects. The patch demonstrated significant efficacy in reducing ADHD symptoms, even when worn for shorter periods.
A phase 3 study demonstrated lisdexamfetamine dimesylate's effectiveness in reducing ADHD symptoms, with 95% of children showing significant improvement. The medication was well-tolerated, with side effects similar to those of marketed ADHD stimulants.
A new study published in Kidney International found that Fosrenol, a phosphate binder used to treat hyperphosphatemia in CKD Stage 5 patients, did not negatively impact cognitive function deterioration. The two-year trial compared Fosrenol with standard therapy and showed similar declines in cognitive function for both groups.
A recent study found that adults infected with the common cold virus easily transferred the virus to 35% of surfaces touched, and even to an uninfected person by fingertips 18 hours after initial contamination. The virus was also found on a third of objects and surfaces in hotel rooms.
The Phase 3 clinical trial of Fampridine-SR demonstrated a consistent improvement in walking speed, with 34.8% of participants showing a significant increase compared to 8.3% on placebo. The study also showed a statistically significant improvement in leg strength and a reduction in disability reported by daily activities.
Katie Lee Joel joins forces with experts to promote low-phosphorus cooking, sharing six new recipes to honor her grandfather's memory and help patients manage chronic kidney disease. The Kidney Friendly Comfort Foods program aims to show that kidney-friendly foods don't have to be boring.
Three studies presented at CPDD show lisdexamfetamine dimesylate has lower euphoric effects and delayed peak effects compared to d-amphetamine sulfate. Lisdexamfetamine dimesylate also produces liking effects in healthy adults with previous history of stimulant abuse.
A nationwide survey shows a significant gap in understanding of type 2 diabetes management, with patients feeling knowledgeable about their condition but not following treatment regimens as prescribed. The Diabetes Roundtable advocates for a team-centered approach involving patients, physicians, and educators to improve care outcomes.
Phase II and phase III clinical trials demonstrate DAYTRANA's effectiveness in reducing ADHD symptoms, including improvements in behavior and classroom performance. The patch formulation provides a once-daily treatment option for children aged 6-12 with ADHD.
A phase II trial of NRP104 demonstrated a statistically significant reduction in ADHD symptoms comparable to mixed amphetamine salts extended-release. The medication was well-tolerated and showed improved behavior, academic productivity, and reduced symptoms in children aged 6 to 12 years with ADHD.
Long-acting mixed amphetamine salts (MAS XR) and immediate-release mixed amphetamine salts showed similar efficacy to short- or long-acting methylphenidates. Stimulant medications like amphetamines and methylphenidate are more effective in treating ADHD symptoms, according to the study.
A neurocognitive study found that mixed amphetamine salts extended release improved divided attention, visuospatial working memory, visual scanning, and mental flexibility in adults with ADHD. Participants who received the medication showed significant improvements in response speed and maintained accuracy when switched to placebo.
A large-scale phase IV trial found FOSRENOL significantly reduced daily tablet burden and improved patient satisfaction, while maintaining mean serum phosphorus control. Higher initial doses of FOSRENOL more rapidly controlled hyperphosphatemia without increasing adverse events.
Since the introduction of PREVNAR, antibiotic-resistant invasive pneumococcal disease (IPD) has decreased by 87% among all ages, 98% among children under two, and 79% among adults over 65. The vaccine has also reduced IPD caused by penicillin-resistant strains targeted by the vaccine.
Researchers found that denosumab significantly increased BMD at the total hip (3.6% vs. -0.6%) and lumbar spine (6.7% vs. -0.8%) in women administered the therapy twice yearly, with a rapid onset of action. The study also showed improvements in distal 1/3 radius and total body BMD.
A phase 2 trial evaluating denosumab, a RANK Ligand inhibitor, found the treatment increased BMD at the lumbar spine and total hip in postmenopausal women with low BMD. The therapy demonstrated rapid and sustained responses in bone metabolism.
A Phase 3 study found that Aranesp treatment achieved and maintained target hemoglobin levels, reducing red blood cell transfusions by 24%. The extended dosing schedule may allow physicians to treat anemia on the same schedule as chemotherapy.
A long-term study showed that AMG 531 increased platelet counts in patients with immune thrombocytopenic purpura (ITP), with 47% of patients experiencing a durable response. The treatment was generally well-tolerated, but some serious adverse events were reported.
In the Phase 2 study, Aranesp demonstrated a significant erythroid response and improvements in hemoglobin levels and fatigue among low-risk MDS patients. The study found that 70% of patients with no prior erythropoietic agent use achieved an erythroid response and 67% reached target hemoglobin levels.
Researchers found that CBZ-ERC significantly reduced manic and mixed symptoms for patients with Bipolar I Disorder. The study also showed that the medication was generally well-tolerated, with only 14.3% of patients experiencing a relapse.
The TEMPO study demonstrated that over three-quarters of patients treated with Enbrel plus methotrexate experienced no progression of joint damage. Additionally, patients treated with this combination therapy showed a significant improvement in physical function compared to those receiving either treatment alone.
A Phase 2 trial of denosumab found significant increases in bone mineral density across various sites, including the lumbar spine, total hip, and distal radius. The study suggests denosumab may offer a new approach to treating osteoporosis by targeting RANK Ligand.
The investigational methylphenidate transdermal system (MTS) demonstrated statistically significant reductions in ADHD symptoms and was well-tolerated in patients aged 6 to 12. MTS improved behavior, math performance, and overall symptom reduction compared to placebo.
A two-year, open-label trial demonstrated that adults with ADHD experienced significant long-term symptom control when treated with once-daily ADDERALL XR. The treatment showed a good tolerability profile and was significantly associated with improved quality of life.
A study found that ADDERALL XR significantly improved driving safety and performance in patients with ADHD, measured by a 2.5-point reduction in their average Driving Safety Score. The medication also showed significant effects on ADHD symptom control, improving attention and reducing lapses in attention.
Children with ADHD treated with the MTS patch showed statistically significant improvements in behavior and math performance. The phase II and III studies demonstrated a 56% reduction in ADHD symptoms, paving the way for potential approval by the FDA.
A Phase 2 study of Aranesp(R) demonstrates a 77% overall response rate in low-risk MDS patients with anemia. Patients who had never received erythropoietic therapy responded well to Aranesp, while those with prior treatment showed continued efficacy.
EQUETRO demonstrates significant reduction in manic symptoms for patients previously taking valproate or lithium, with average YMRS scores decreasing by 10.8 and 11.6 points, respectively. The medication is an effective treatment option for acute manic and mixed episodes associated with Bipolar I Disorder.
Adults with ADHD experience significant financial losses due to lower educational attainment and achievement, as well as difficulties in the workplace. The study found that adults with ADHD had an average loss of $8,900 to $15,400 per year in household income.
Panitumumab demonstrated a median survival time of 37.6 weeks and tumor response for 29% of patients with mCRC. The study confirmed safety and efficacy findings previously reported, suggesting panitumumab as an additional treatment option for managing the disease.
A large community-based clinical trial showed a significant reduction in febrile neutropenia and chemotherapy dose reductions among older patients receiving Neulasta. The study found that Neulasta reduced the incidence of serious adverse events, including hospitalizations and pneumonia.
A Phase 3 study of Aranesp dosed every three weeks achieved a 91% success rate in maintaining target hemoglobin levels, with 72% of patients sustaining the level over 16 weeks. The treatment showed reduced need for red blood cell transfusions and consistent adverse event profile.
A randomized head-to-head study demonstrates Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly in terms of transfusion rates and hemoglobin achievement. The study involved over 1,200 patients with chemotherapy-induced anemia and found similar outcomes between the two treatment groups.